OpenAI acquired Orchestra Bio to strengthen Rosalind, its AI platform for life sciences, by adding software that helps drug developers coordinate research, studies and development tasks.

Orchestra's platform uses AI agents to track progress, flag issues and streamline collaboration across internal teams and outside vendors.

The ChatGPT parent company aims to connect scientific research with the planning and execution needed to advance drug candidates, addressing a drug development process that can take a decade or longer.

OpenAI also described how disruptions in one area can cascade into others, using a manufacturing failure as an example that could push back a clinical trial start. Orchestra agents are intended to map downstream schedule impacts, collect relevant context, and help teams evaluate response options.

Drug Researchers Turn To AI

Anthropic, an OpenAI rival, recently reported that its Claude model designed 318,000 candidate proteins in 64 hours to target scorpion venom toxins. Seventeen designs met binding criteria in laboratory tests.

However, the experiment did not establish whether the proteins could neutralize venom, underscoring the gap between generating promising candidates and developing effective treatments.

The results highlight how AI companies are competing to accelerate drug discovery, while acquisitions and partnerships aim to extend the technology beyond research into the complex process of developing and delivering new treatments.

Separately, OpenAI cited work with Novo Nordisk and Moderna as examples of how it can collaborate with drugmakers.

"Alongside researchers and our partners, we aim to make more discoveries possible and help new medicines reach patients sooner," the company wrote.